Volume 28, Number 7—July 2022
Dispatch
Determining Infected Aortic Aneurysm Treatment Using Focused Detection of Helicobacter cinaedi
Table 1
Variables | Total, n = 10 | H. cinaedi, n = 4 | Non–H. cinaedi, n = 6 |
---|---|---|---|
Age, median (IQR) |
77 (70.5–83.0) |
77.5 (70.0–84.3) |
77 (71.0–82.3) |
Sex | |||
M | 8 | 3 | 5 |
F |
2 |
1 |
1 |
Comorbidity | |||
Diabetes mellitus | 3 | 2 | 1 |
Chronic kidney disease | 1 | 1 | 0 |
Cancer |
2 |
1 |
1 |
Steroid use |
1 |
0 |
1 |
Sign or symptom | |||
Pain | 8 | 3 | 5 |
Fever | 7 | 3 | 4 |
Shock |
1 |
0 |
1 |
Laboratory findings, median (IQR) | |||
Leukocytes, × 103 cells/μL | 9.6 (8.8–11.0) | 8.4 (7.4–9.5) | 1.1 (9.5–17.2) |
C-reactive protein, mg/dL | 7.6 (5.1–22.1) | 4.3 (3.8–5.1) | 21.6 (11.0–23.6) |
Procalcitonin, ng/dL |
0.19 (0.05–0.76) |
0.14 (0.04–0.38) |
0.38 (0.08–1.53) |
Aneurysm diameter, mm, median (IQR) |
40.5 (32.8–44.8) |
32.5 (25.5–39.8) |
44.5 (37.3–55.5) |
Aneurysm location | |||
Thoracic aorta | 1 | 1 | 0 |
Thoracoabdominal aorta | 1 | 0 | 1 |
Abdominal aorta |
8 |
3 |
5 |
Aneurysm form | |||
Saccular | 7 | 4 | 3 |
Fusiform |
3 |
0 |
3 |
Rupture |
3 |
0 |
3 |
Aortoduodenal fistula |
2 |
0 |
2 |
Surgery | |||
Emergency | 3 | 0 | 3 |
Urgent | 2 | 1 | 1 |
Elective | 5 | 3 | 2 |
Endovascular |
1 |
1 |
0 |
Nonsurgical treatment only |
2 |
1 |
1 |
Death | 1 | 0 | 1 |
*IQR, interquartile range.
Page created: May 05, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.